Compare PulteGroup, Inc. (PHM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs Sana Biotechnology Inc — how do they compare? PulteGroup, Inc. trades at $112.12 (market cap $21.63B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: PulteGroup, Inc. is far larger — about 25.9× Sana Biotechnology Inc's market cap, and PulteGroup, Inc. pays a 0.92% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and Sana Biotechnology Inc for 23 Days on average.
| PHM | SANA | |
|---|---|---|
Market Cap | $21.63B | $836.71M |
Volume | 2,324,729 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $5.92 |
52-Week Low | $110.11 | $2.68 |
Typical Hold Time | 91 Days | 23 Days |
Enterprise Value | $22.04B | $749.96M |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $113.53, up 1.07% on the day, amid a bearish technical signal and mixed earnings history. The stock shows solid profitability with a net margin of 11.62% and ROE of 14.9%, but faces headwinds from rising mortgage rates impacting the housing sector. Recent news highlights institutional buying interest despite broader market pressures.
Outlook: Analyst consensus is bullish with a $139.80 price target, but risks include interest rate sensitivity and earnings misses. Investment opportunity lies in attractive valuation (P/E 11.6) if housing demand stabilizes, though macroeconomic volatility remains a key concern for near-term performance.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative earnings, and substantial cash burn. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral conditions. Recent earnings have been mixed with two misses and one beat against expectations, while analyst sentiment remains overwhelmingly positive with 82% buy ratings.
The outlook hinges on SANA's clinical pipeline success and future revenue generation capabilities. Investment opportunity exists in the company's promising biotechnology platform and strong analyst support, but risks include continued cash burn, lack of current revenue, and execution challenges in bringing therapies to market. The stock represents a high-risk, high-reward biotechnology investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
